Illumina Inc
$ 187.96
-2.97%
07 Aug - close price
- Market Cap 29,251,719,000 USD
- Current Price $ 187.96
- High / Low $ 196.04 / 187.46
- Stock P/E 37.33
- Book Value 18.80
- EPS 5.19
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE 0.32 %
- 52 Week High 207.00
- 52 Week Low 88.00
About
Illumina, Inc. is an American company. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in San Diego, California.
Analyst Target Price
$195.16
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-30 | 2026-04-30 | 2026-02-05 | 2025-10-30 | 2025-07-31 | 2025-05-08 | 2025-02-06 | 2024-11-04 | 2024-08-06 | 2024-05-02 | 2024-02-08 | 2023-11-09 |
| Reported EPS | 1.31 | 1.15 | 1.35 | 1.34 | 1.19 | 0.97 | 0.86 | 1.14 | 0.36 | 0.09 | 0.14 | 0.33 |
| Estimated EPS | 1.23 | 1.06 | 1.23 | 1.17 | 1.01 | 0.94 | 0.92 | 0.88 | 0.9 | 0.11 | 0.12 | 0.14 |
| Surprise | 0.08 | 0.09 | 0.12 | 0.17 | 0.18 | 0.03 | -0.06 | 0.26 | -0.54 | -0.02 | 0.02 | 0.19 |
| Surprise Percentage | 6.5041% | 8.4906% | 9.7561% | 14.5299% | 17.8218% | 3.1915% | -6.5217% | 29.5455% | -60% | -18.1818% | 16.6667% | 135.7143% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ILMN
2026-08-06 20:41:54
Illumina director Keith A. Meister reported that private investment funds advised by Corvex Management LP sold 741,127 shares of Illumina common stock between August 4-5, 2026. The sales occurred in multiple transactions at weighted-average prices ranging from $196.74 to $203.28 per share. This transaction significantly reduced the indirect holdings of Corvex-advised funds, though Meister maintains a direct holding of 6,780 shares.
2026-08-06 17:24:00
Illumina Inc. (ILMN) stock dropped 3.08% on Thursday, closing at $193.72, underperforming the broader market. This marks the second consecutive day of losses for the stock, as the S&P 500 Index and Dow Jones Industrial Average also saw declines.
2026-08-05 21:25:00
Illumina Inc. (ILMN) stock declined 1.55% on Wednesday, closing at $199.87. This underperformance occurred on a mixed trading day, with the Dow Jones Industrial Average rising and the S&P 500 Index falling. The stock is currently 3.44% below its 52-week high achieved on August 3rd.
2026-08-03 20:41:08
Illumina's Chief Legal Officer, Scott M. Davies, sold 615 shares of common stock on July 30, 2026, at a price of $200.00 per share. This transaction, executed under a Rule 10b5-1 trading plan, leaves him with 20,338 shares directly owned. The sale, valued at $123,000, was an open market or private transaction.
2026-08-03 17:25:00
Illumina Inc. (ILMN) stock declined by 3.38% on Monday, closing at $198.16, despite an overall strong performance by the stock market. The S&P 500 Index and the Dow Jones Industrial Average both saw gains, making Illumina's drop noteworthy and ending a four-day winning streak for the company's shares.
2026-08-03 16:41:08
Illumina reported strong Q2 2026 earnings, exceeding revenue and EPS estimates, driven primarily by robust clinical market growth. The company raised its full-year guidance for revenue and EPS, emphasizing the sustained demand for clinical sequencing, particularly with the NovaSeq X platform. TIKR's valuation model suggests a potential 22% total return for Illumina stock by 2030, reflecting confidence in the structural growth drivers rather than one-time gains.
